Hologic has agreed to acquire Reveal Genomics, adding the HER2DX assay to its oncology diagnostics portfolio and expanding genomic testing options for breast cancer, according to a company statement.
SOPHiA GENETICS and Myriad Genetics are collaborating to develop a decentralized prostate cancer companion diagnostic, aiming to enable local labs to assess DNA repair deficiencies using the PrGIS biomarker in clinical trials.
Castle Biosciences’ new data presented at ACG 2026 show the TissueCypher test offers objective risk stratification for Barrett’s esophagus progression, providing information beyond standard histopathology.
A study found that Quest Diagnostics’ Haystack MRD ctDNA test detected colorectal cancer recurrence with up to 100% specificity, outperforming CEA testing in DYNAMIC trial patient specimens.
Read More
A Stanford-led study found that Resero Bio’s uRARE-seq urine cfRNA test can non-invasively detect bladder cancer, assess tumor grade, and predict therapy response in 683 patient samples.
Read More
Using microfluidic shear stress, the system detaches living cells from excised tissue to support pathology workflows and downstream diagnostic testing.
Read More
Astrin Biosciences has expanded access to its Certitude breast cancer blood test to 48 states through OpenLoop Health. The assay showed 92% sensitivity and 93% specificity in clinical validation.
Read More
Project HOPE, funded by The Labcorp Charitable Foundation, has launched a two-year Madison, Wisconsin, initiative with local clinics to expand PSA testing and prostate cancer care for uninsured men facing access barriers.
Read More
Abbott has launched SimpleScreen CRC, an FDA-approved blood test for colorectal cancer screening in average-risk adults, reporting 81.1% sensitivity and 90.4% specificity in a 48,000-patient study.
Read More
An ancillary analysis of the phase III NRG/RTOG 0815 trial shows Veracyte’s Decipher Prostate test can predict which intermediate-risk prostate cancer patients benefit from adding hormone therapy to radiation.
Read More
An FDA advisory panel voted 7-2 that the benefits of GRAIL’s Galleri multi-cancer early detection blood test outweigh its risks for adults 50 and older, supporting its premarket approval application.
Read More
Lucid Diagnostics reports new Medicare, CPT, and ICD-10 panel recommendations supporting reimbursement and coding for its EsoGuard and EsoCheck esophageal cancer tests, advancing billing and clinical tracking pathways.
Read More
A study led by Augusta University found 100% concordance between Nabsys OhmX electronic genome mapping and standard cytogenetic methods in detecting pathogenic variants in AML and CML bone marrow samples.
Read More
A University of Oxford study of 275,000 patients found that tracking trends in 23 routine blood tests over time improved cancer risk prediction in those with unexplained weight loss, compared to single test results.
Read More
bioAffinity Technologies has received a Hong Kong patent for its CyPath Lung diagnostic platform, expanding intellectual property protection for its noninvasive lung cancer detection technology in the Asian market.
Read More
The College of American Pathologists has updated 14 Cancer Protocols, mandating the Breast Phyllodes Tumor protocol for accreditation and revising breast biomarker and GIST molecular testing criteria, according to CAP.
Read More
The investigational PANXEON liquid biopsy detected early-stage pancreatic cancer with 87% sensitivity and low false-positive rates in a multi-center study of nearly 1,800 patients.
Read More
Mayo Clinic researchers report that AI-enabled spatial analysis of standard pathology slides can predict pancreatic cancer recurrence risk more accurately than volume-based methods, according to a study in Clinical Cancer Research.
Read More